to both RAL and EVG can emerge. However, DTG has shown a superior barrier to HIV resistance compared to RAL and EVG. Importantly it has not been observed that HIV can develop resistance mutations against DTG when the drug is used in first line therapy. This unique resistance profile might make DTG useful in thinking about a functional cure for HIV. In this review, we summarize recent studies on potential approaches towards a functional HIV cure, the resistance profile of DTG, and discuss our understandings on how DTG might play a role in helping to achieve a functional HIV cure.
Current Potential HIV Cure Strategies
A few years ago, there was debate as to whether or not HIV is curable, with many arguing against this possibility (Purcell et al. 2013) . Now, however, there is increasing evidence and confidence that at least a functional cure for HIV might be achieved.Monitoring of the latest studies on HIV cure/remission has revealed a number of strategies that are being pursued (Barouch and Deeks 2014; Dey and Berger 2015; Martin and Siliciano 2015; Pace and Frater 2014; Thornhill et al. 2015) .
Most important is the case of the Berlin Patient, the first person who has been cured of HIV (Allers et al. 2011; Hutter et al. 2009 ). This patient had lived with HIV for 11 years while under therapy with ART and, in 2007, developed acute myeloid leukemia. Then he received a stem cell transplant from a donor who was homozygous for a 32-bp deletion in the CCR5 allele, which provides resistance against HIV-1 infection. The patient remains free of any sign of HIV rebound and disease progression over the past 8 years after transplantation and discontinuation of ART.
This case provides a proof of principle that a HIV cure might be possible. However, this approach is not practical and it remains necessary to find one that is more satisfying and broadly applicable. Jiang et al. 2015) . These compounds are potential candidates for advancing HIV eradication.
The immunologic strategies for killing the virus-producing cells include therapeutic vaccines, monoclonal antibodies, and immune checkpoint inhibitors (Barouch and Deeks 2014; Katlama et al. 2013 ). This strategy is currently under investigation in clinical trials.
For example, a trial in the UK will evaluate the combination of vorinostat, a HDAC inhibitor, and vaccination (Thornhill et al. 2015) . To attack the reservoir, it is important to locate the sites at which the latently infected cells reside. Current approaches mainly focus on CD4 + T-cells in blood. But other cell types or tissues may also harbour latent virus, including monocytes, macrophages, and T-memory stem cells. A large proportion of latently infected cells may also reside in tissues outside of blood, including lymphoid tissue, the central nervous system (CNS), spleen and lymph nodes. New assays to identify and measure latent reservoirs of HIV-infected cells need to be validated (Bruner et al. 2015) .
Nowadays, ART is widely recognized as being able to inhibit HIV replication and reduce viral load in HIV-infected patients, but the effect of ART drugs on viral latency and immune activation is still poorly understood (Hladik 2015) . It has been reported that early ART during acute HIV infection reduced the size of reservoir (Ananworanich et al. 2015; Ananworanich et al. 2012; Archin et al. 2012) and it is possible that very early ART may be curative for HIV. A
French girl was infected with HIV when she was born in 1996. She received a prophylactic treatment for six weeks from the day she was born. She was switched to ART from three months of age until about the age of five years six months when ART was stopped. She returned to the clinic after discontinuation of ART for a full year. It was found that she remained undetectable in terms of viral load in her blood at that time and no treatment was given. She has now been in Table 1 .
It is important to point out that DTG can be distinguished from both RAL and EVG in the sense that very limited cross-resistance exists among these compounds Wainberg and Han 2015) . Some mutations in integrase that are potentially involved in resistance to DTG were reported at positions at F121, S153, G118, E138, and R263 in vitro and in vivo (Kobayashi et al. 2011; Quashie et al. 2013b) . R263K was initially reported as the most common substitution identified in cell culture selections with DTG and was shown to confer only moderate resistance to DTG (fold change, FC = 2.3-fold) (Quashie et al. 2012) . Biochemical studies also showed that R263K decreased strand transfer activity and viral replication capacity.
D r a f t
Later, it was reported that R263K was present in several treatment-experienced, INSTI-naïve patients in the SAILING clinical trial (Cahn et al. 2013 ).
In the development of HIV resistance to drugs, it is common that a primary mutation confers a low level of resistance while reducing replication capacity and that the subsequent occurrence of a combination of secondary mutations increase levels of drug resistance while restoring viral replication fitness. In cell culture selections with DTG, R263K was often observed together with H51Y. While the latter had no effects on resistance to DTG, the addition of H51Y to R263K increased resistance to DTG to ~8-fold, while dramatically decreasing viral replication capacity by ~90% and enzyme strand transfer activity by ~80% (Mesplede et al. 2013) . Other studies have
shown that R263K in combination with M50I, G118R, H51Y, E138K, T66I, N155H or M184I/V slightly increased resistance to DTG, but did not restore viral replication capacity (Anstett et al. 2015; Liang et al. 2015; Quashie et al. 2013a; Quashie et al. 2015; Wares et al. 2014 ).
Interestingly, no additional compensatory mutations have been identified for DTG, even in cell culture selection experiments conducted over more than four years .
It is generally believed that the higher genetic barrier of DTG to resistance of HIV-1 is due to its slow dissociation rate from integrase-DNA complexes in comparison to RAL and EVG (Geretti et al. 2012; Hightower et al. 2011; Osman et al. 2015; Wainberg and Han 2015) . Some studies have shown that DTG has an extended linker which allows its difluorophenyl group to enter farther into the pocket within the integrase active site than other INSTIs and that DTG has the ability to adjust its structure and conformation in response to structural changes within the active sites of RAL-and EVG-resistant integrases, compared to RAL and EVG ( Fig. 1) . A recent study measured the genetic and amino-acid diversity of Env/gp160 from two HIV-1 primary isolates that were grown in the presence of increasing concentrations of DTG or RAL over the course of 38-55 weeks. It was found that treatment with DTG led to less HIV-1 genetic and amino-acid diversity over time, as compared to treatment with RAL or the absence of drug . These results may also help to explain the absence of emergent resistance mutations for any drug in treatmentnaive individuals treated with DTG, as a result of more limited HIV evolution in patients treated with the latter drug.
How Might DTG Be Useful in a Functional Cure for HIV?
Until now, the use of DTG in first-line therapy has not yielded any resistance mutations in HIV-patients in the clinic. Data from tissue culture selection with DTG revealed that the development of an initial HIV resistance mutation for DTG was associated with greatly reduced replication capacity. Due to its efficacy and high barrier to resistance, DTG is becoming one of the preferred choices for HIV therapy in both treatment-naïve and treatment-experienced patients (Cruciani and Malena 2015) . Since DTG has a truly unique resistance profile, in which the resistance mutations that are selected by the drug result in a severe impairment in replication fitness, concomitant with a greatly diminished capacity to generate additional mutations, we D r a f t 11 believe that DTG might be able to be used as part of a strategy aimed at attaining a functional HIV cure if not complete HIV eradication.
For one thing, if DTG is imperious to the occurrence of resistance in first-line therapy, then it might be possible to use it as monotherapy in treatment-naive patients. In this case, even if the R263K mutation is selected, the viruses would not be able to grow well, due to impaired replication capacity. Following interruption of DTG-containing treatment, viruses might begin to replicate from the latent reservoirs, as observed in other ART treatment interruption trials.
However, re-initiation of DTG monotherapy might then convert these viruses into DTG-resistant attenuated forms. Logically, a number of cycles of DTG treatment interruption followed by reinitiation of DTG monotherapy could conceivably convert all the HIV in the body, even that within latent reservoirs, as they emerge out of latency, to a replication impaired form. As viral reservoirs decay over a number of cycles, the reduced HIV-1 reservoirs would not be able to rebound once interruption of ART takes place (Fig. 2) . If this is true, such an approach might lead to a functional cure of HIV disease if all residual viruses were significantly impaired in viral replication and thereby reduced in numbers and if further compensatory mutations were unable to develop Wainberg and Han 2015) . Recent studies have shown that early initiation of antiretroviral therapy can greatly reduce the size of the HIV reservoir and help to achieve optimal immune reconstitution (Buzon et al. 2014; Conway and Perelson 2015; Hocqueloux et al. 2013 ).
Obviously, a cure approach will depend on a number of factors, such as the size of the latent reservoir, the rate of reactivation of latent viruses, and the strength of the host immune response However, strategies aimed at reducing the latent reservoir size and/or boosting host immune responses, combined with the DTG interruption approach, may enhance the probability of a possible cure. In the Visconti study, some patients remained aviremic while being off therapy for a median of 89 months, after having received a median of 36 months of ART (Thornhill et al. 2015) . It might therefore be reasonably predicted that DTG interruption and resumption over several cycles might also be able to contribute to a purging of the numbers of archived wild-type viruses, especially if combined with other approaches.
A proof of concept study should ideally first be conducted in animal models, such as rhesus macaques that are infected by simian immunodeficiency virus (SIV) or humanized mice that are infected by HIV. Of course, until such animal studies are complete, we will be without data to prove that this approach will actually lead to the replacement of wild-type viruses in the reservoirs by DTG-resistant defective viruses. Additionally, the rate at which defective viruses may replace WT viruses within the reservoirs is unknown, and this process may take decades before it yields a clinically significant decrease in the size of the WT reservoirs. In this regard, it is important to note that viral reservoirs become established early during the course of infection, as has been shown in rhesus monkeys infected with SIV (Whitney et al. 2014 ). The latter is thus an excellent model to study the ability of defective viruses to replace replication-competent WT viruses.
In addition, the extent to which the viral reservoirs must be diminished to attain long-term remission remains unknown. Therefore, even if defective viruses replace 90% of the WT viruses in reservoirs, this may not suffice to allow immunological control of residual viral replication to occur following treatment interruption. This issue is of concern for all current cure strategies and shown that no further resistance mutations have been observed after more than four years of DTG selective pressure . Moreover, it is possible that DTG will be the drug of choice in a variety of prevention strategies, such as Treatment as Prevention. Should this turn out to be the case, there might be profound implications both for the prevention of HIV transmission and HIV cure and/or remission.
Conclusions and Perspectives
The past several years have seen important advances in research toward a HIV cure. Increasing evidence has suggested that HIV-1 might be eradicated or that a functional cure might be possible. However, more detailed understanding of the biology of the latent viral reservoir and the relevant virus-specific immune response is needed, in addition to improved latency assays to quantitate the viral reservoir (Bruner et al. 2015) . 
